News

This year's fierce winter is now about to bring a big dose of misery to the 60 million Americans who suffer from seasonal allergies. Experts predict a fast-peaking, intense spring allergy season. Moisture accumulated from heavy snow and excessive rain has nurtured mold, and will fuel tree-pollen production-all of which will trigger an early and severe allergy season.

Tissue, please?

Atlanta-Americans say having itchy, watery eyes is their most annoying allergy symptom, according to a new national survey.

Golden, CO-Noridian, the Medicare carrier for 14 western states, has proposed limiting coverage for monitored anesthesia care (MAC) for cataract surgery, except for severely ill patients.

Paris-Neurotech will collaborate with INSERM, the French National Institute for Health and Medical Research, to develop a technology platform and therapies for retinal diseases.

Alameda, CA-The U.S. Patent & Trademark Office said InSite Vision Inc.'s patent gives the company sole rights to the use of azalide antibiotic formulations as a topical treatment of ocular infections.

Mountain View, CA-IRIDEX Corp. has completed enrollment in a clinical trial for its TTT4CNV, to determine whether trans-pupillary thermotherapy (TTT) laser treatment can reduce the risk of vision loss for patients with occult wet age-related macular degeneration (AMD).

Irvine, CA-ISTA Pharmaceuticals is regrouping after an FDA advisory committee said the company's tests of ovine hyal-uronidase (Vitrase) failed to demonstrate sufficient statistical evidence to support its efficacy in treating vitreous hemorrhage.

Irvine, CA-In early April, cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) became commercially available for the treatment of eye inflammation associated with keratoconjunctivitis sicca. The introduction of the product marks the first therapeutic option for people with dry eye by not only providing temporary relief of dry eye, but also treating the associated ocular inflammation, according to the company.

Boston-Multiple intravitreal injections of rhuFab V2 (Genentech Inc., San Francisco) are well-tolerated and appear to have favorable biologic activity for the treatment of exudative age-related macular degeneration (AMD), said Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston and the Center for Eye Research, principal investigator for that trial.

Royal Oak, MI-Optical coherence tomography (OCT) may be more sensitive than fluorescein angiography in detecting vitreofoveal traction and differences in thickness in the different areas of the macula in patients with persistent diabetic macular edema (DME). While fluorescein angiography remains the standard in imaging, Cynthia Carvalho-Recchia, MD, suggested an adjunctive role for OCT in patients with DME.

Philadelphia-Gene therapy has successfully restored the visual function of blind dogs with a rare congenital retinal disease, according to early research results. This breakthrough holds implications for the treat- ment of several human retinal degenerative diseases within the next several years.

Orlando-Deep anterior lamellar keratoplasty (DALK) is performed to manage anterior corneal disorders and keratoconus, and posterior lamellar keratoplasty (PLK) is used to manage posterior (endothelial) corneal disorders.

Editor's Note: Sight is precious, but its impairment does not preclude achievement. Helen Keller, Ray Charles, and Andrea Bocelli are just a few successful people that come to my mind immediately. There are many others!

Cincinnati-The third and fourth issues of the 2002 Video Journal of Cataract and Refractive Surgery, published by Robert H. Osher, MD, are available free to residency programs in the United States and ophthalmologists around the world.

Rochester, NY-Bausch & Lomb is launch-ing its most ambitious TV advertising campaign ever, marking a new creative direction and marketing strategy for the 150-year-old company.

Mississauga, Ontario-TLC Vision Corp. has acquired American Eye Instruments, of Gold Beach, OR, for an undisclosed amount.

Portland, OR-Researchers in the Casey Eye Institute at Oregon Health & Science University (OHSU) began participation in February in a gene therapy trial for patients with age-related macular degeneration (AMD).

Fort Lauderdale, FL-The Association for Research in Vision and Ophthalmology (ARVO) turns 75 years this year. To commemorate this major milestone, several special events are planned during the annual meeting from May 4 to 8 in Fort Lauderdale, FL.